

**Table 108: Summary of Data Supporting CHB Rate Used in Analysis: United Kingdom** Northern/Western Europe

Meta-analysis not done for United Kingdom. Used CHB rate = 0.54% (range 0.30% to 0.60%)

Country	Study, survey year(s)*	Region	Population and sampling method	Sex	HBsAg		lower CI	upper CI	RE weight (%)	FE weight (%)	Reference	Access No	Ref No.
					Sample positive (n)	(%)							
United Kingdom	Pendelton, 2007	national	National prevalence estimated from 1) population numbers (UK-born and migrants); and 2) CHB rates of 0.25% for UK-born and country-specific rates for migrants derived from the literature	both	NA	0.54%	—	—	NA	NA	Pendelton S., P. Wilson-Webb. "Rising Curve: Chronic Hepatitis B in the U.K." Hepatitis B Foundation UK, 2007	not in PubMed	—
United Kingdom	Boxall, 1990-1991	Birmingham	Pregnant women attending antenatal clinic at inner-city hospital	females	3,522	0.56%	0.31%	0.81%	NA	NA	Boxall E., S. Skidmore. "The prevalence of hepatitis B and C in an antenatal population of various ethnic origins." Epidemiol Infect 113(3):523-8.	7527780	1389
United Kingdom	Gay, 1996	England and Wales	Anonymous residual diagnostic sera submitted to microbiology labs as part of the PHLS serological surveillance programme	both	3,781	0.37%	0.18%	0.56%	NA	NA	Gay NJ, L.M. Hesketh, et al. "The prevalence of hepatitis B infection in adults in England and Wales." Epidemiol Infect 122(1):133-8.	10098796	1390
United Kingdom	Giraudon, 2000-2007	London	Pregnant women; routine testing at 30 National Health Service maternity clinics 2000-2007; 96.4% of women were tested; no sample size reported	females	not reported	1.17%	0.30%	2.40%	NA	NA	Giraudon, I., J. Ford, et al. (2009). "Antenatal screening and prevalence of infection: surveillance in London, 2000-2007." Euro Surveill 14(9):8-12	19317973	1388
United Kingdom	Health Protection Agency, 2007	10 regions in England	Pregnant women; routine testing at antenatal clinics during 4Q 2007	females	17,252	0.60%	0.48%	0.72%	NA	NA	Sentinel Surveillance of Hepatitis Testing. Antenatal HBsAg teting. Health Protection Agency, 2009. <a href="http://www.hpa-bioinformatics.org.uk/hepc/results.php">http://www.hpa-bioinformatics.org.uk/hepc/results.php</a> (Accessed 5/20/09)	not in PubMed	—
United Kingdom	Health Protection Agency, 2008	10 regions in England	Pregnant women; routine testing at antenatal clinics during 2008	females	62,031	0.60%	0.54%	0.66%	NA	NA	Sentinel Surveillance of Hepatitis Testing. Annual results: January to December 2008. Health Protection Agency. <a href="http://www.hpa-bioinformatics.org.uk/hepc/results.php">http://www.hpa-bioinformatics.org.uk/hepc/results.php</a> (Accessed 10/20/10)	not in PubMed	—

\* indicates publication year; survey year not reported

**Table 109: Summary of Data Supporting CHB Rate Used in Analysis: Germany**

Northern/Western Europe

Meta-analysis not done for Germany. Used CHB rate = 0.60% (range 0.40% to 0.80%)

Country	Study, survey year(s)*	Region	Population and sampling method	Sex	HBsAg		lower CI	upper CI	RE weight (%)	FE weight (%)	Reference	Access No	Ref No.
					Sample positive (n)	(%)							
Germany	Thierfelder, 1998	national	National Health Survey conducted in 1998; stratified sampling according to state and community size used to select 120 sampling points representative of the German population; people from military barracks, old people's homes, hospital, nursing homes and prisons were excluded; "probably an under-estimate"	both	6,748	0.60%	0.40%	0.60%	NA	NA	Thierfelder, W., W. Hellenbrand, et al. (2001). "Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998." Eur J Epidemiol 17(5):429-35	11855576	1391

\* indicates publication year; survey year not reported

**Table 110: Summary of Data Supporting CHB Rate Used in Analysis: France** Northern/Western Europe

Meta-analysis not done for France. Used CHB rate = 0.68% (range 0.44% to 1.05%)

Country	Study, survey year(s)*	Region	Population and sampling method	Sex	HBsAg			RE weight (%)	FE weight (%)	Reference	Access No	Ref No.
					Sample positive (n)	lower CI (%)	upper CI (%)					
France	Meffre, 2003-2004	national	Stratified survey of members of the National Insurance Scheme; population of metropolitan France	both	14,419	0.68%	0.44%	1.05%	NA	NA Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs du virus de l'hépatite B chez les assurés sociaux du régime général de France métropolitaine, 2003-2004. <a href="http://www.invs.sante.fr/publications/2005/analyse_descriptif_140205/rapport_analyse_descriptive.pdf">www.invs.sante.fr/publications/2005/analyse_descriptif_140205/rapport_analyse_descriptive.pdf</a>	not in PubMed	—
France	Meffre, 2004	national	General population age 18-80 yo using the national health insurance system; stratified, multistage sampling in five regions;	both	14,416	0.65%	0.45%	0.93%	NA	NA Meffre C., Y Le Strat, et al. (2010). Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors." <i>J Med Virol</i> 82(4):546-5	20166185	1397
France	Roudot-Thoraval, 1989*	Paris	Pregnant french women (non-immigrants); routine antenatal testing at four hospitals during 1984-1998	female	1,294	0.85%	0.35%	1.35%	NA	NA Roudot-Thoraval, F., F. Kouadja, et al. (1989). "[Prevalence of HBs antigen carriers and markers of B virus replication in a population of pregnant women, in France]." <i>Gastroenterol Clin Biol</i> 13(4):353-6.	2737390	1396
France	Denis, 1994-1998	Limoges	Pregnant women; routine antenatal testing at a French Provincial Hospital during 1984-1998; 15% immigrants	female	22,859	0.65%	0.55%	0.75%	NA	NA Denis F., S. Ranger-Rogez, et al. (2004). "Screening of pregnant women for hepatitis B markers in a French Provincial University Hospital (Limoges) during 15 years." <i>Eur J Epidemiol</i> 19(10):973-8.	15575357	1395

\* indicates publication year; survey year not reported

**Table 111: Summary of Data Supporting CHB Rate Used in Analysis: Ireland**

Northern/Western Europe

Meta-analysis not done for Ireland. Used CHB rate = 0.35% (range 0.26% to 0.44%)

Country	Study, survey year(s)*	Region	Population and sampling method	Sex	Sample size (n)	HBsAg positive (%)	lower CI	upper CI	RE weight (%)	FE weight (%)	Reference	Access No	Ref No.
Ireland	Healy, 1998-2000	Dublin	Pregnant women routinely tested at antenatal clinics at Rotunda Maternity Hospital 1998-2000	females	16,222	0.35%	0.26%	0.44%	NA	NA	Healy, C.M., M.T. Cafferkey, et al. (2001). "Antenatal hepatitis B screening - is there a need for a national policy?" Ir Med J 94(4):111-2, 114	11440046	1393
Ireland	Tilson, 2005	Dublin	Rate selected for model of cost-effectiveness of hepatitis B vaccination in Ireland; used rate in pregnant women routinely tested at antenatal clinics at Rotunda Maternity Hospital 2005 (0.9%) as the upper estimate and a rate 50% lower than this as the lower estimate	females	not reported	0.72%	0.48%	0.96%	NA	NA	Tilson, L., L. Thornton, et al. (2008). "Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation." Eur J Public Health 18(3):275-82	18160389	1392

\* indicates publication year; survey year not reported

**Table 112: Summary of Data Supporting CHB Rate Used in Analysis: Netherlands**

Northern/Western Europe

Meta-analysis not done for Netherlands. Used CHB rate = 0.41% (range 0.11% to 0.72%)

Country	Study, survey year(s)*	Region	Population and sampling method	Sex	HBsAg		lower CI	upper CI	RE weight (%)	FE weight (%)	Reference	Access No	Ref No.
					Sample positive (n)	(%)							
Netherlands	Baaten, 2004	Amsterdam	Participants of health monitoring survey of the general Amsterdam population; weighted by sex, age, and ethnicity so that they are representative for the general Amsterdam population	both	1,364	0.41%	0.11%	0.72%	NA	NA	Baaten, G.G., G.J. Sonder, et al. (2007) "Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004." J Med Virol 79(12):1802-10.	17935187	1394

\* indicates publication year; survey year not reported